Price (delayed)
$59.02
Market cap
$3.37B
P/E Ratio
5.01
Dividend/share
N/A
EPS
$11.79
Enterprise value
$3.17B
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In
There are no recent dividends present for AGIO.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.